Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection-Reference-Cited by-同舟云学术

Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection

Published:2022-08-16 Issue:8 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Watanabe Fumiya¹²^ORCID,Furuuchi Koji³^ORCID,Hanada Kazuhiko¹^ORCID,Fujiwara Keiji³^ORCID,Uesugi Fumiko³,Hiramatsu Miyako³,Yoshiyama Takashi³,Shiraishi Yuji³,Kurashima Atsuyuki³,Ohta Ken³,Morimoto Kozo³⁴^ORCID

Affiliation:

1. Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Tokyo, Japan

2. Department of Pharmacy, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan

3. Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan

4. Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan

Abstract

Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated. The objectives of this study were to characterize the pharmacokinetics of CFZ in pulmonary NTM disease treatment and to investigate the relationship between the steady-state CFZ serum concentration and adverse effects.

Funder

Nagai Memorial Research Scholarship

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00441-22

Reference32 articles.

1. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

2. Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria